IGF1R and non-small cell lung carcinoma: In contrast, while IGFR meets three of these criteria, IGF1R antagonists have been studied in several solid tumors [24, 25] and did not demonstrate benefit in phase III testing in NSCLC, and were therefore not investigated further in this study [26].